Haemophilus influenzae type b Conjugate Vaccine

Haemophilus influenzae type b Conjugate Vaccine Brand Names

ActHIB | Hiberix | HibTITER | PedvaxHIB

What is Haemophilus influenzae type b Conjugate Vaccine

The Haemophilus influenzae type b conjugate vaccine is an intramuscular vaccine indicated for prevention of infection from Haemophilus influenzae type b (Hib).

Hib disease occurs primarily among children under 5 years of age, and the risk of invasive Hib disease is increased in daycare attendees; lower socioeconomic groups; household contacts of cases; or individuals with asplenia, sickle cell disease, or other antibody deficiency syndromes.

The primary vaccine series against Haemophilus influenzae type b (Hib) consists of 2 or 3 doses (depending on the product used) given between the ages of 2 and 6 months plus a booster dose ideally given between 12 to 15 months of age.

Different formulations of the Hib vaccine are commercially available; each formulation utilizes purified capsular polysaccharide of Hib conjugated via covalent bonding to another antigen to increase immunogenicity.

Liquid PedvaxHIB contains Hib capsular polysaccharide (i.e., polyribosylribitol phosphate, PRP) covalently linked to a meningococcal outer membrane protein (OMP) carrier whereas ActHIB and Hiberix are PRP-tetanus toxoids (PRP-TT) conjugate Hib vaccines.

Although these antigens are derived from other microorganisms, the Hib vaccine does not confer immunity against these other organisms. The Hib vaccines are used in primary series and booster immunization in infants as young as 6 weeks.

ActHIB was FDA approved in September 1996, and Liquid PedvaxHIB was FDA approved in February 1990.

Hiberix, a formulation initially indicated only as a booster dose after receipt of a primary series with a vaccine licensed for primary immunization (ActHIB or Liquid PedvaxHIB), was FDA approved in August 2009.

In January 2016, the Hiberix indication was expanded to include patients 6 weeks through 18 months.

Indications

  • Haemophilus influenzae type b prophylaxis

Side Effects

  1. anaphylactic shock
  2. anaphylactoid reactions
  3. angioedema
  4. anorexia
  5. apnea
  6. diarrhea
  7. drowsiness
  8. erythema
  9. erythema multiforme
  10. fever
  11. Guillain-Barre syndrome
  12. hypotonia
  13. inconsolable crying
  14. injection site reaction
  15. irritability
  16. lethargy
  17. lymphadenopathy
  18. nausea
  19. rash
  20. renal failure (unspecified)
  21. restlessness
  22. seizures
  23. syncope
  24. urticaria
  25. vomiting

Monitoring Parameters

  • laboratory monitoring not necessary

Contraindications

  • agammaglobulinemia
  • anticoagulant therapy
  • breast-feeding
  • coagulopathy
  • corticosteroid therapy
  • fever
  • Guillain-Barre syndrome
  • hemophilia
  • human immunodeficiency virus (HIV) infection
  • hypogammaglobulinemia
  • immunosuppression
  • infants
  • infection
  • intravenous administration
  • laboratory test interference
  • latex hypersensitivity
  • leukemia
  • lymphoma
  • Native American patients
  • neonates
  • neoplastic disease
  • pregnancy
  • premature neonates
  • severe combined immunodeficiency (SCID)
  • thrombocytopenia
  • vitamin K deficiency

Interactions

  • Ocrelizumab
  • Siponimod